| Title: |
Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review |
| Authors: |
Specchio, Nicola; Auvin, Stéphane; Strzelczyk, Adam; Brigo, Francesco; Villanueva, Vicente; Trinka, Eugen |
| Source: |
Epilepsia Open ; volume 9, issue 6, page 2017-2036 ; ISSN 2470-9239 2470-9239 |
| Publisher Information: |
Wiley |
| Publication Year: |
2024 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Status epilepticus (SE) is a life‐threatening emergency with high morbidity and mortality. In people with epilepsy, the management of SE is focused on early medical treatment. Stiripentol is a third‐generation antiseizure medication (ASM) approved for refractory generalized tonic–clonic seizures in Dravet syndrome. The aim of this systematic review was to evaluate the effectiveness and safety of stiripentol in reducing the incidence of SE in patients with Dravet syndrome or any epilepsy characterized by recurrent SE. The PubMed and Cochrane databases were systematically searched, and gray literature was hand‐searched. Search results were screened by title and abstract; studies with data on the effect of stiripentol on SE outcomes, including the cessation of SE, reduction in number of SE episodes, or reduction in hospitalizations, were included. Of 66 records identified, 17 studies were eligible for inclusion, of which 15 were human studies ( n = 474; aged 1.1–78 years), and two were animal experiments. Results of retrospective or prospective observational studies showed that stiripentol as add‐on therapy to ASMs such as clobazam or valproate reduced the incidence of SE in patients with Dravet syndrome or other developmental and epileptic encephalopathies (DEEs). A mean of 68% of patients (range 41%–100%) had a ≥50% reduction in SE episodes from baseline, and 26%–100% of patients (mean 77%) became SE‐free after stiripentol initiation. Moreover, this review found stiripentol, used as acute treatment, may also be effective for the cessation of super‐refractory SE, but data are limited to three retrospective case series. Stiripentol was generally well‐tolerated. In conclusion, stiripentol reduces the incidence of SE episodes in patients with Dravet syndrome and potentially other DEEs, and it promotes cessation of super‐refractory SE in patients with and without a history of seizures. Plain Language Summary Status epilepticus (SE) is a life‐threatening, long‐lasting seizure occurring in patients with/without ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1002/epi4.13036 |
| Availability: |
https://doi.org/10.1002/epi4.13036; https://onlinelibrary.wiley.com/doi/pdf/10.1002/epi4.13036 |
| Rights: |
http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.47955EB9 |
| Database: |
BASE |